Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea

Molecular Pharmacology

Volumn 55, Issue 6, 1999, Pages 1006-1010

  Glover, Richard E ^a   Ivy, Edward D ^b   Orringer, Eugene P ^b   Maeda, Hiroshi ^c   Mason, Ronald P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYHEMOGLOBIN; HYDROXYUREA;

ADULT; ARTICLE; CASE REPORT; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; ELECTRON SPIN RESONANCE; HUMAN; MALE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; THROMBOCYTE ACTIVATION;

EID: 0032977037     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.55.6.1006     Document Type: Article

References (40)

1. Brittain HA, Eckman JR, Swerlick RA, Howard RJ and Wick TM (1993) Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion. Blood 81:2137-2143.
2. Buchanan GR and Holtkamp CA (1983) Evidence against enhanced platelet activity in sickle cell anaemia. Br J Haematol 54:595-603.
3. Bunn HF (1997) Pathogenesis and treatment of sickle cell disease. N Engl J Med 337:762-769.
4. Charache S (1991) Hydroxyurea as treatment for sickle cell anemia. Hematol Oncol Clin North Am 5:571-583.
5. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O and Orringer EP (1996) Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. Medicine (Baltimore) 75:300-326.
6. Croizat H (1994) Circulating cytokines in sickle cell patients during steady state. Br J Haematol 87:592-597.
7. Duits AJ, Pieters RC, Saleh AW, van Rosmalen E, Katerberg H, Berend K and Rojer RA (1996) Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol 81: 96-98.
8. Eriksson LEG (1994) Binding of nitric oxide to intact human erythrocytes as monitored by electron paramagnetic resonance. Biochem Biophys Res Commun. 203: 176-181.
9. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S and Bunn HF (1990) Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 323:366-372.
10. Hall DM, Buettner GR, Matthes RD and Gisolfi CV (1994) Hyperthermia stimulates nitric oxide formation: Electron paramagnetic resonance detection of NO-heme in blood. J Appl Physiol 77:548-553.
11. Head CA, Brugnara C, Martinez-Ruiz R, Kacmarek RM, Bridges KR, Kuter D, Bloch KD and Zapol WM (1997) Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest 100:1193-1198.
12. Henry Y and Cassoly R (1973) Chain non-equivalence in nitric oxide binding to hemoglobin. Biochem Biophys Res Commun 51:659-665.
13. Jiang J, Jordan SJ, Barr DP, Gunther MR, Maeda H and Mason RP (1997) In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol Pharmacol 52:1081-1086.
14. Kaul DK, Fabry ME and Nagel RL (1996) The pathophysiology of vascular obstruction in the sickle syndromes. Blood Rev 10:29-44.
15. Kim-Shapiro DB, King SB, Bonifant CL, Kolibash CP and Ballas SK (1998) Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin. Biochim Biophys Acta 1380:64-74.
16. Kosaka H, Sawai Y, Sakaguchi H, Kumura E, Harada N, Watanabe M and Shiga T (1994) ESR spectral transition by arteriovenous cycle in nitric oxide hemoglobin of cytokine-treated rats. Am J Physiol 266:C1400-C1405.
17. Kwon NS, Stuehr DJ and Nathan CF (1991) Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med 174:761-767.
18. Liu X, Miller MJS, Joshi MS, Sadowska-Krowicka H, Clark DA and Lancaster JR (1998) Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem 273:18709-18713.
19. Lofvenberg E and Wahlin A (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41:375-381.
20. 3+ in MgO. Physical Rev 105:801-805.
21. Natarajan M, Udden MM and McIntire LV (1996) Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. Blood 87:4845-4852.
22. Nyholm S, Thelander L and Graslund A (1993) Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea. Biochemistry 32:11569-11574.
23. Orringer EP and Parker JC (1992) Hydroxyurea and sickle cell disease. Hematol Pathol 6:171-178.
24. Pacelli R, Taira J, Cook JA, Wink DA and Krishna MC (1996) Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet 347:900.
25. Pauling L, Itano HA, Singer SJ and Wells IC (1949) Sickle cell anemia, a molecular disease. Science 110:543-548.
26. Pawloski JR, Swaminathan RV and Stamler JS (1998) Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation. Circulation 97:263-267.
27. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH and Klug PP (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639-1644.
28. Rees DC, Cervi P, Grimwade D, O'Driscoll A, Hamilton M, Parker NE and Porter JB (1995) The metabolites of nitric oxide in sickle-cell disease. Br J Haematol 91: 834-837.
29. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN and Nienhuis AW (1990) Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 322:1037-1045.
30. Rodgers GP, Roy MS, Noguchi CT and Schechter AN (1988) Use of selective vasodilation in treatment of sickle cell disease. Am J Pediatr Hematol Oncol 10:351-356.
31. Rodgers GP, Walker EC and Podgor MJ (1993) Is "relative" hypertension a risk factor for vaso-occlusive complications in sickle cell disease? Am J Med Sci 305: 150-156.
32. Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD and Rowinsky EK (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 91:1533-1541.
33. Sato K, Akaike T, Sawa T, Miyamoto Y, Suga M, Ando M and Maeda H (1997) Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea. Jpn J Cancer Res 88:1199-1204.
34. Solovey A, Lin Y, Browne P, Choong S, Wayner E and Hebbel RP (1997) Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 337:1584-1590.
35. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR and Loscalzo J (1992) Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A 89:7674-7677.
36. Stolze K and Nohl H (1990) EPR studies on the oxidation of hydroxyurea to paramagnetic compounds by oxyhemoglobin. Biochem Pharmacol 40:799-802.
37. Svistunenko DA, Davies NA, Wilson MT, Stidwill RP, Singer M and Cooper CE (1997) Free radical in blood: A measure of haemoglobin autoxidation in vivo. J Chem Soc Perkin Trans 2:2539-2543
38. Westenberger U, Thanner S, Ruf HH, Gersonde K, Sutter G and Trentz O (1990) Formation of free radicals and nitric oxide derivative of hemoglobin in rats during shock syndrome. Free Radic Res Commun 11:167-178.
39. Westwick J, Watson-Williams EJ, Krishnamurthi S, Marks G, Ellis V, Scully MF, White JM and Kakkar VV (1983) Platelet activation during steady state sickle cell disease. J Med 14:17-36.
40. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K and Cheung A (1997) Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 129:507-516.